Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of EMA401 (olodanrigan) for post-herpetic neuralgia
jRCT2080223760Phase 2Terminated
- Sponsor
- Novartis
- Start
- Dec 2017
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of olodanrigan in postherpetic neuralgia (PHN) (4 arms), sponsored by Novartis. Started Dec 2017; status: terminated.
02
Drugs
olodanrigan
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on jRCT2080223760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223760.